These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19703879)

  • 1. Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features.
    Gilbert FJ; Warren RM; Kwan-Lim G; Thompson DJ; Eeles RA; Evans DG; Leach MO;
    Radiology; 2009 Aug; 252(2):358-68. PubMed ID: 19703879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography.
    van Zelst JCM; Mus RDM; Woldringh G; Rutten MJCM; Bult P; Vreemann S; de Jong M; Karssemeijer N; Hoogerbrugge N; Mann RM
    Radiology; 2017 Nov; 285(2):376-388. PubMed ID: 28609204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers.
    Obdeijn IM; Mann RM; Loo CCE; Lobbes M; Voormolen EMC; van Deurzen CHM; de Bock G; ; Hooning MJ
    Breast Cancer Res Treat; 2020 Jun; 181(3):581-588. PubMed ID: 32333294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
    Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers.
    Huo Z; Giger ML; Olopade OI; Wolverton DE; Weber BL; Metz CE; Zhong W; Cummings SA
    Radiology; 2002 Nov; 225(2):519-26. PubMed ID: 12409590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammographic, US, and MR imaging phenotypes of familial breast cancer.
    Schrading S; Kuhl CK
    Radiology; 2008 Jan; 246(1):58-70. PubMed ID: 18096529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
    Shimada S; Yoshida R; Nakashima E; Kitagawa D; Gomi N; Horii R; Takeuchi S; Ashihara Y; Kita M; Akiyama F; Ohno S; Saito M; Arai M
    Breast Cancer; 2019 Nov; 26(6):846-851. PubMed ID: 30980249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
    Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
    Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
    Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH
    Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer.
    Griebsch I; Brown J; Boggis C; Dixon A; Dixon M; Easton D; Eeles R; Evans DG; Gilbert FJ; Hawnaur J; Kessar P; Lakhani SR; Moss SM; Nerurkar A; Padhani AR; Pointon LJ; Potterton J; Thompson D; Turnbull LW; Walker LG; Warren R; Leach MO;
    Br J Cancer; 2006 Oct; 95(7):801-10. PubMed ID: 17016484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
    Phi XA; Greuter MJW; Obdeijn IM; Oosterwijk JC; Feenstra TL; Houssami N; de Bock GH
    Breast; 2019 Jun; 45():82-88. PubMed ID: 30904701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results.
    Sardanelli F; Podo F; D'Agnolo G; Verdecchia A; Santaquilani M; Musumeci R; Trecate G; Manoukian S; Morassut S; de Giacomi C; Federico M; Cortesi L; Corcione S; Cirillo S; Marra V; ; Cilotti A; Di Maggio C; Fausto A; Preda L; Zuiani C; Contegiacomo A; Orlacchio A; Calabrese M; Bonomo L; Di Cesare E; Tonutti M; Panizza P; Del Maschio A
    Radiology; 2007 Mar; 242(3):698-715. PubMed ID: 17244718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age ≥ 50 years: evidence from an individual patient data meta-analysis.
    Phi XA; Houssami N; Obdeijn IM; Warner E; Sardanelli F; Leach MO; Riedl CC; Trop I; Tilanus-Linthorst MM; Mandel R; Santoro F; Kwan-Lim G; Helbich TH; de Koning HJ; Van den Heuvel ER; de Bock GH
    J Clin Oncol; 2015 Feb; 33(4):349-56. PubMed ID: 25534390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density.
    Riedl CC; Luft N; Bernhart C; Weber M; Bernathova M; Tea MK; Rudas M; Singer CF; Helbich TH
    J Clin Oncol; 2015 Apr; 33(10):1128-35. PubMed ID: 25713430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
    Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
    JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition.
    Obdeijn IM; Loo CE; Rijnsburger AJ; Wasser MN; Bergers E; Kok T; Klijn JG; Boetes C
    Breast Cancer Res Treat; 2010 Jan; 119(2):399-407. PubMed ID: 19876732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
    Warner E; Plewes DB; Hill KA; Causer PA; Zubovits JT; Jong RA; Cutrara MR; DeBoer G; Yaffe MJ; Messner SJ; Meschino WS; Piron CA; Narod SA
    JAMA; 2004 Sep; 292(11):1317-25. PubMed ID: 15367553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
    Saadatmand S; Vos JR; Hooning MJ; Oosterwijk JC; Koppert LB; de Bock GH; Ausems MG; van Asperen CJ; Aalfs CM; Gómez Garcia EB; Meijers-Heijboer H; Hoogerbrugge N; Piek M; Seynaeve C; Verhoef C; Rookus M; Tilanus-Linthorst MM;
    Int J Cancer; 2014 Dec; 135(12):2940-9. PubMed ID: 24789418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Risk Category and Screening Round on the Performance of an MR Imaging and Mammography Screening Program in Carriers of the BRCA Mutation and Other Women at Increased Risk.
    Vreemann S; Gubern-Mérida A; Schlooz-Vries MS; Bult P; van Gils CH; Hoogerbrugge N; Karssemeijer N; Mann RM
    Radiology; 2018 Feb; 286(2):443-451. PubMed ID: 29040037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer.
    Liljegren A; von Wachenfeldt A; Azavedo E; Eloranta S; Grundström H; Ståhlbom AK; Sundbom A; Sundén P; Svane G; Ulitzsch D; Arver B
    Breast Cancer Res Treat; 2018 Apr; 168(3):655-666. PubMed ID: 29318406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.